• Latest
  • Trending
Sputnik V Covid Vaccine 92% Effective, Russia Says

Sputnik V Covid Vaccine 92% Effective, Russia Says

November 12, 2020
Can Nigeria Sell Crude Oil in Naira to the Dangote Refinery?

Can Nigeria Sell Crude Oil in Naira to the Dangote Refinery?

March 2, 2021
Bill to Amend Nigeria’s Revenue Sharing Formula Passes Second Reading at Senate, 20% Proposed for Sovereign Fund

Nigerian Senate Affirms New Service Chiefs’ Appointment

March 2, 2021
Nigerian-born Professor Akande Gets UK Nomination as Representative to UN Commission

Nigerian-born Professor Akande Gets UK Nomination as Representative to UN Commission

March 2, 2021

Morning Show

March 2, 2021
Buhari Orders Nigeria’s Central Bank to Stop Issuing Forex for Food Importation

Ransom Payments Will Continue to Prosper Kidnapping, President Buhari Says After Release of Zamfara Schoolgirls

March 2, 2021
Three South Sudan Military Generals Die of Covid-19

Three South Sudan Military Generals Die of Covid-19

March 2, 2021

BREAKING: Nigeria Takes Delivery of 3.92m Doses of AstraZeneca Vaccines

March 2, 2021
Nigeria: DSS Releases Kano Governor’s Aide Dismissed for Criticising Buhari

Nigeria: DSS Releases Kano Governor’s Aide Dismissed for Criticising Buhari

March 2, 2021
‘Indecently Dressed Tourists’ in Zanzibar to Pay Fine

‘Indecently Dressed Tourists’ in Zanzibar to Pay Fine

March 2, 2021
Niger Opposition Leader Charged With Plot to Overthrow Government

Niger Opposition Leader Charged With Plot to Overthrow Government

March 2, 2021
Chad Opposition Leader Pulls Out of Presidential Race

Chad Opposition Leader Pulls Out of Presidential Race

March 2, 2021
Behind the Numbers: MTN Nigeria’s Record-breaking N1.3tn Revenue Year

Behind the Numbers: MTN Nigeria’s Record-breaking N1.3tn Revenue Year

March 2, 2021
Oil Prices Fall on Renewed Coronavirus Concerns as China Cases Mount

Oil Price Rebounds to $66 Ahead of OPEC Meeting

March 2, 2021
Ex-President Bartomeu, Others Arrested as Police Raid FC Barcelona

Ex-President Bartomeu, Others Arrested as Police Raid FC Barcelona

March 2, 2021
Chinese Vaccines Sweep Much of the World, Despite Western Concerns

Chinese Vaccines Sweep Much of the World, Despite Western Concerns

March 2, 2021
Betting on Death of Petrol Cars, Volvo to Go All Electric By 2030

Betting on Death of Petrol Cars, Volvo to Go All Electric By 2030

March 2, 2021
Name Schoolgirls’ Abductors, Nigerian Socio-cultural Groups Tell Zamfara Governor

Name Schoolgirls’ Abductors, Nigerian Socio-cultural Groups Tell Zamfara Governor

March 2, 2021
New York Governor Cuomo under Investigation By FBI for Nursing Home Deaths

Calls for Cuomo’s Resignation Mount as 3rd Sexual Harassment Accuser Emerges

March 2, 2021
Terrorists Attack UN Base in Nigeria’s Northeast Borno State, 25 Aid Workers Trapped

Terrorists Attack UN Base in Nigeria’s Northeast Borno State, 25 Aid Workers Trapped

March 2, 2021
Nigeria Threatens Second Lockdown Over Low Compliance with Covid-19 Protocols

Covid-19: Nigeria to Vaccinate 70% of Population Before 2022, SGF Mustapha Says

March 2, 2021
Ghana’s President Akufo-Addo Becomes First Recipient of Covid Vaccine from COVAX

Ghana’s President Akufo-Addo Becomes First Recipient of Covid Vaccine from COVAX

March 2, 2021
Zamfara Schoolgirls in Northwest Nigeria Released Early Hours of Tuesday

Zamfara Schoolgirls in Northwest Nigeria Released Early Hours of Tuesday

March 2, 2021
ARISE Newsnight

ARISE Newsnight

March 1, 2021
ARISE XCHANGE

ARISE XCHANGE

March 1, 2021
Nigerian Government Opens Portal for Covid Vaccination E-registration

Nigerian Government Opens Portal for Covid Vaccination E-registration

March 1, 2021

ARISE NEWSDAY

March 1, 2021
Former France President Sarkozy Found Guilty of Corruption, Sentenced to Prison

Former France President Sarkozy Found Guilty of Corruption, Sentenced to Prison

March 1, 2021

Global Business Report

March 1, 2021

Morning Show

March 1, 2021
Ramaphosa to Address South Africans on Covid 

South Africa Drops Coronavirus Alert Level After Dip in New Infections 

March 1, 2021
en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianpt Portugueseru Russianes Spanish
No Result
View All Result
Tuesday, March 2, 2021
Arise News
  • HOME
  • Breaking
  • Global
  • Regional
  • BUSINESS
  • Politics
    • US ELECTION
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates
Arise News
  • HOME
  • Breaking
  • Global
  • Regional
  • BUSINESS
  • Politics
    • US ELECTION
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates
No Result
View All Result
Arise News
No Result
View All Result
Home Global

Sputnik V Covid Vaccine 92% Effective, Russia Says

November 12, 2020
Reading Time: 8min
0 0
0
Sputnik V Covid Vaccine 92% Effective, Russia Says
Share on FacebookShare on Twitter

 Russia’s Sputnik V vaccine is 92% effective at protecting people from Covid-19 according to interim trial results, the country’s sovereign wealth fund said on Wednesday, as Moscow rushes to keep pace with Western drug makers in the race for a shot.

The initial results are only the second to be published from a late-stage human trial in the global effort to produce vaccines that could halt a pandemic that has killed more than 1.2 million people and ravaged the world economy.

The results are based on data from the first 16,000 trial participants to receive both shots of the two-dose vaccine, the Russian Direct Investment Fund (RDIF), which has been backing its development and marketing it globally, said.

“We are showing, based on the data, that we have a very effective vaccine,” said RDIF head Kirill Dmitriev, adding that it was the sort of news that the vaccine’s developers would talk about one day with their grandchildren.

The analysis was conducted after 20 participants in the trial developed Covid-19 and examined how many had received the vaccine versus a placebo.

That is significantly lower than the 94 infections in the trial of a vaccine being developed by Pfizer Inc and BioNTech.

To confirm the efficacy rate, Pfizer said it would continue its trial until there were 164 COVID-19 cases.

RDIF said the Russian trial would continue for six more months and data from the study will also be published in a leading international medical journal following a peer review.

European stocks and US stock futures extended their gains slightly after Russia’s announcement.

Russia’s announcement follows swiftly on from results posted on Monday by Pfizer and BioNTech, which said their shot was also more than 90% effective.

The Russian results are another boost to other Covid-19 vaccines currently in development and are a proof of concept that the disease can be halted with a vaccination.

Experts said knowledge about the trial’s design and protocol was sparse, making it difficult to interpret the figures released on Wednesday.

Scientists have raised concerns about the speed at which Moscow has worked, giving regulatory go-ahead for the shot and launching a mass vaccination programme before full trials to test its safety and efficacy had been completed.

Russia registered its COVID-19 vaccine for public use in August, the first country to do so, though the approval came before the start of the large-scale trial in September.

The so-called phase three trial of the shot developed by the Gamaleya Institute is taking place in 29 clinics across Moscow and will involve 40,000 volunteers in total, with a quarter receiving a placebo shot.

The chances of contracting Covid-19 were 92 percent lower among people vaccinated with Sputnik V than those who received the placebo, the RDIF said.

That is well above the 50% effectiveness threshold for Covid-19 vaccines set by the US Food and Drug Administration.

“I can see no a priori reason to disbelieve these results, but it’s so very hard to comment, because there is so little data there,” said Danny Altmann, a professor of Immunology at Imperial College London.

He said while the Russian release was similar in its level of detail to the one from Pfizer and BioNTech, the key difference was that Pfizer’s release came against a backdrop of a wealth of published data on how the trial was designed, its protocol, and what its endpoints were.

The results of the early-stage trials were peer-reviewed and published in September in The Lancet medical journal.

The Russian drug is named Sputnik V after the Soviet-era satellite that triggered the space race, a nod to the project’s geopolitical importance for Russian President Vladimir Putin.

The vaccine is designed to trigger a response from two shots administered 21 days apart, each based on different viral vectors that normally cause the common cold: human adenoviruses Ad5 and Ad26.

The Pfizer and BioNTech vaccine uses messenger RNA (mRNA) technology and is designed to trigger an immune response without using pathogens, such as actual virus particles.

Russia is also testing a different vaccine, produced by the Vector Institute in Siberia, and is on the cusp of registering a third, Putin said on Tuesday, adding that all of the country’s vaccines were effective.

RDIF said as of November 11 no serious side effects had been reported during the Sputnik V Phase III trial.

Some volunteers had short-term minor adverse effects such as pain at the injection site, flu-like symptoms including fever, weakness, fatigue, and headaches, it said.

Successful vaccines are seen as crucial to restoring daily life around the world by helping end the health crisis that shuttered businesses and put millions out of work.

Russia registered the vaccine for domestic use in August and has also inoculated 10,000 people considered to be at high risk of Covid-19 outside of the trial.

Putin has said Russia expects to start mass vaccinations by the end of the year.

“The publication of the interim results of the post-registration clinical trials that convincingly demonstrate Sputnik V vaccine’s efficacy gives way to mass vaccination in Russia against Covid-19 in the coming weeks,” Alexander Gintsburg, director of the Gamaleya Institute, said.

Moscow is rolling out a large network of vaccination rooms and residents who want the shot may be able to get it as early as next month if large volumes of doses are supplied by then, Deputy Mayor Anastasia Rakova said on October 30.

However, production challenges remain. Earlier estimates that Russia could produce 30 million doses of the vaccine this year have since been scaled down.

Moscow aims to produce 800,000 doses this month, industry minister Denis Manturov has said, followed by 1.5 million in December. But significantly higher volumes of output per month are expected from early 2021.

Manturov cited issues with scaling up production from small- to large-volume bioreactors, while Putin last month cited issues with the availability of equipment.

In late October, the vaccination of new volunteers was temporarily paused due to high demand and a shortage of doses.

Officials have said domestic production of the vaccine will be used first to meet Russia’s needs.

RDIF, however, has also struck several international supply deals, amounting to 270 million doses in total.

It is expected these will in large part be produced in other countries and RDIF has previously announced a deal to manufacture 300 million doses in India and an undisclosed amount of doses in Brazil, China and South Korea.

Trials have also begun in Belarus, and are on track to begin soon in the United Arab Emirates, Venezuela and India.

Russia reported 19,851 new coronavirus infections in the past 24 hours and a record high of 432 deaths. At 1,836,960, its overall case tally is the fifth largest in the world, behind the United States, India, Brazil and France.

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2020 Arise News - Part of the Arise Media Group.

No Result
View All Result
  • HOME
  • Breaking
  • Global
  • Regional
  • BUSINESS
  • Politics
    • US ELECTION
  • Entertainment
  • Sports
  • TECH
  • Health
  • VIDEOS
  • Covid-19 Updates

© 2020 Arise News - Part of the Arise Media Group.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist